Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems

Dec 21, 2021
Posted in: News, Investor updates, Press & Media

Home » Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems

Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems

Dec 21, 2021
Posted in: News, Investor updates, Press & Media

Tim Boreham revisits Imagion Biosystems’ potential in this 5-1/2 page article profiling the company and discussing its recent milestones.

Read the article here.

The Unanswered Question in Prostate Cancer Diagnosis

September 24, 2026

Separating lethal disease from indolent disease remains the persistent difficulty, and molecular MRI may offer a way to see the difference. Prostate cancer is the

The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials

September 4, 2026

Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

June 3, 2026

Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems

Biotech Daily — Dr Boreham’s Crucible: Imagion Biosystems

Related Articles

The Unanswered Question in Prostate Cancer Diagnosis

The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list